Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 230 articles:
HTML format



Single Articles


    April 2021
  1. OZNUR M, Topcu B, Celikkol A
    Predictive value of noninvasive indices in chronic hepatitis B virus-related fibrosis.
    Eur J Gastroenterol Hepatol. 2021;33:577-582.
    PubMed     Abstract available


    March 2021
  2. SERWAH MA, Omar SA, Khedr MS, Abdel-Hamid AES, et al
    Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97270.
    PubMed     Abstract available


    February 2021
  3. SAHIN M, Sucu P, Serin E, Yetim A, et al
    Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C.
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97302.
    PubMed     Abstract available


  4. SAUD LRC, Chagas AL, Maccali C, Pinto PVA, et al
    Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior?
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97300.
    PubMed     Abstract available


    January 2021
  5. VIJAYALEKSHMI B, Sharma A, Prabhu SB, Nair SC, et al
    Reticuloendothelial activation correlates with disease severity and predicts mortality in severe alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97323.
    PubMed     Abstract available


  6. EL-NAHAAS SM, Rady NH, Malek S, Serag K, et al
    Changes in serum interferon-gamma-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97309.
    PubMed     Abstract available


  7. YILMAZ B, Kayadibi H, Yeniova AO, Koseoglu H, et al
    The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  8. PESTANA NF, Equi CMA, Gomes CP, Cardoso AC, et al
    Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    November 2020
  9. LASHEN SA, Metawea MI, Shaaban A
    Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002015.
    PubMed     Abstract available


  10. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018).
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002012.
    PubMed     Abstract available


  11. LITHY RM, Elbaz T, H Abdelmaksoud A, M Nabil M, et al
    Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001972.
    PubMed     Abstract available


  12. RUIZ I, Fourati S, Ahmed-Belkacem A, Rodriguez C, et al
    Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000002003.
    PubMed     Abstract available


  13. TANG Y, Zhou H, Xiang Y, Cui F, et al
    The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001978.
    PubMed     Abstract available


  14. KAYADIBI H, Yilmaz B, Ozgur Yeniova A, Koseoglu H, et al
    Development and evaluation of a novel noninvasive index for predicting significant fibrosis, advanced fibrosis, and cirrhosis in patients with chronic hepatitis B infection.
    Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001973.
    PubMed     Abstract available


    October 2020
  15. ATEF M, Zayed N, Salama R, Abdel Alem S, et al
    Is urinary beta2-microglobulin a reliable marker for assessment of renal tubular dysfunction in chronic hepatitis B patients receiving tenofovir therapy?
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001977.
    PubMed     Abstract available


  16. OMRAN M, Fouda M, Abdelwahab AO, Nabeel MM, et al
    P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001962.
    PubMed     Abstract available


  17. WANG X, Chen HZ, Liu WT, Liu M, et al
    The association of plasma high-density lipoprotein cholesterol levels and cirrhosis development in obese patients with chronic hepatitis B: a cohort study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001965.
    PubMed     Abstract available


    September 2020
  18. STEIN K, Stoehr A, Klinker H, Teuber G, et al
    Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001923.
    PubMed     Abstract available


  19. AKSOY B, Baran M, Cagan Appak Y, Sag E, et al
    Efficiency of azathioprine monotherapy for maintenance treatment of autoimmune hepatitis in children.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001930.
    PubMed     Abstract available


  20. TOVO CV, Ahlert M, Panke C, de Mattos AZ, et al
    Treatment of hepatitis B virus infection in chronic infection with HBeAg-positive adult patients (immunotolerant patients): a systematic review.
    Eur J Gastroenterol Hepatol. 2020 Sep 15. doi: 10.1097/MEG.0000000000001907.
    PubMed     Abstract available


  21. SEONG G, Sinn DH, Kang W, Gwak GY, et al
    Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase.
    Eur J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1097/MEG.0000000000001915.
    PubMed     Abstract available


    August 2020
  22. ABDO M, Rabiee A, Abdellatif Z, Abdel Alem S, et al
    Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001903.
    PubMed     Abstract available


  23. NUMAO H, Shimaya K, Kakuta A, Shibutani K, et al
    The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001887.
    PubMed     Abstract available


  24. KIM JH, Kang SH, Lee M, Choi HS, et al
    Individualized surveillance of chronic hepatitis B patients according to hepatocellular carcinoma risk based on PAGE-B scores.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001870.
    PubMed     Abstract available


  25. BEYAN C, Beyan E
    Mean platelet volume to platelet ratio may not be reliable to determine the severity of fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:1067.
    PubMed    


  26. ELSADEK HM, Abdelbaser ES, Emara MH, Soliman HH, et al
    Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Eur J Gastroenterol Hepatol. 2020;32:1046-1053.
    PubMed     Abstract available


    July 2020
  27. OKAY G, Biberci Keskin E, Akkoyunlu Y, Bolukcu S, et al
    Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents.
    Eur J Gastroenterol Hepatol. 2020 Jul 14. doi: 10.1097/MEG.0000000000001849.
    PubMed     Abstract available


  28. DI LELLO FA, Blejer J, Alter A, Bartoli S, et al
    Seroprevalence of hepatitis E virus in Argentinean blood donors.
    Eur J Gastroenterol Hepatol. 2020 Jul 14. doi: 10.1097/MEG.0000000000001853.
    PubMed     Abstract available


  29. GUAN X, Xing F, Li Y
    Alcohol consumption increases the incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis but not in patients with hepatitis C cirrhosis.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001837.
    PubMed     Abstract available


  30. GARRIDO-ESTEPA M, Latasa P, Flores-Herrera J, Garcia Comas L, et al
    Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001841.
    PubMed     Abstract available


  31. CHEN SH, Huang CL, Chiang IP, Chang TC, et al
    Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001833.
    PubMed     Abstract available


  32. MCPHAIL J, Sims OT, Guo Y, Wooten D, et al
    Fibrosis improvement in patients with HCV treated with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.
    PubMed     Abstract available


    June 2020
  33. YUKSEL M, Akturk H, Arikan C
    Immune monitoring of a child with autoimmune hepatitis and type 1 diabetes during COVID-19 infection.
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001804.
    PubMed     Abstract available


  34. ABDEL MOEZ AT, El Hawary YA, Al Balakosy AM
    Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients?
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001790.
    PubMed     Abstract available


  35. DA BL, Lourdusamy V, Kushner T, Dieterich D, et al
    Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001786.
    PubMed     Abstract available


  36. CHON HY, Seo YS, Lee JI, Kim BS, et al
    Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001794.
    PubMed     Abstract available


    May 2020
  37. QIU LX, Liu YL, Lin W, Liu YR, et al
    Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001749.
    PubMed     Abstract available


  38. TSAI MC, Chang KC, Yen YH, Wu CK, et al
    Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
    Eur J Gastroenterol Hepatol. 2020 May 2. doi: 10.1097/MEG.0000000000001711.
    PubMed     Abstract available


  39. CHEUNGPASITPORN W, Thongprayoon C, Ungprasert P, Wijarnpreecha K, et al
    Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005-2014.
    Eur J Gastroenterol Hepatol. 2020;32:650-655.
    PubMed     Abstract available


  40. TANOGLU A
    Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2020;32:664-665.
    PubMed    


    April 2020
  41. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed     Abstract available


  42. CHEN D, Wen S, Wu Z, Gu Y, et al
    Association between effective hepatic blood flow and the severity and prognosis of hepatitis B virus-related acute on chronic liver failure.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001721.
    PubMed     Abstract available


  43. KUMADA T, Toyoda H, Tada T, Yasuda S, et al
    Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001733.
    PubMed     Abstract available


    March 2020
  44. YU HC, Tseng JC, Lu LY, Hu JC, et al
    Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2020 Mar 20. doi: 10.1097/MEG.0000000000001707.
    PubMed     Abstract available


  45. GONZALEZ-COLOMINAS E, Batlle M, Monge-Escartin I, Duran X, et al
    Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response.
    Eur J Gastroenterol Hepatol. 2020 Mar 16. doi: 10.1097/MEG.0000000000001714.
    PubMed     Abstract available


  46. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:378-385.
    PubMed     Abstract available


    February 2020
  47. CHEN Y, Cao D, Li C, Zhang P, et al
    A nomogram for discrimination of non-alcoholic fatty liver disease in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2020 Feb 27. doi: 10.1097/MEG.0000000000001691.
    PubMed     Abstract available


  48. PERISETTI A, Laoveeravat P, Inamdar S, Tharian B, et al
    Hepatitis E virus infection in liver transplant recipients: a descriptive literature review.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001682.
    PubMed     Abstract available


  49. HE Z, Chen J, Wang J, Xu L, et al
    Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection.
    Eur J Gastroenterol Hepatol. 2020 Feb 11. doi: 10.1097/MEG.0000000000001698.
    PubMed     Abstract available


    January 2020
  50. ABDELSAMEEA E, Alsebaey A, Abdel-Razek W, Ehsan N, et al
    Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C.
    Eur J Gastroenterol Hepatol. 2020 Jan 15. doi: 10.1097/MEG.0000000000001672.
    PubMed     Abstract available


    December 2019
  51. GAO X, Duan X, Cai H, Hu Y, et al
    The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001662.
    PubMed     Abstract available


  52. HASSANIN TM, Abdelraheem EM, Abdelhameed S, Abdelrazik M, et al
    Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001647.
    PubMed     Abstract available


  53. RAMACHANDRAN J, Kaambwa B, Muller K, Haridy J, et al
    Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001659.
    PubMed     Abstract available


  54. GAO X, Yang HI, Trinh H, Jeong D, et al
    Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2019 Dec 24. doi: 10.1097/MEG.0000000000001639.
    PubMed     Abstract available


  55. LIONS C, Laroche H, Zaegel-Faucher O, Ressiot E, et al
    Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001640.
    PubMed     Abstract available


  56. AL-AZZAWI Y, Albo B, Fasullo M, Coukos J, et al
    Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1097/MEG.0000000000001583.
    PubMed     Abstract available


  57. DARWEESH SK, Yosry A, Salah M, Zayed N, et al
    Acoustic radiation forced impulse-based splenic prediction model using data mining for the noninvasive prediction of esophageal varices in hepatitis C virus advanced fibrosis.
    Eur J Gastroenterol Hepatol. 2019;31:1533-1539.
    PubMed     Abstract available


    November 2019
  58. POYNARD T, Peta V, Deckmyn O, Pais R, et al
    Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001606.
    PubMed     Abstract available


  59. WANG XH, Jiang XM, Gao PX, Liu Q, et al
    Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001574.
    PubMed     Abstract available


  60. SHOUSHA HI, Saad Y, Saleh DA, Dabes H, et al
    Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001612.
    PubMed     Abstract available


  61. TOSON EA, Shiha GE, El-Sharkawy AM, El-Mezayen HA, et al
    Diagnostic performance of extrinsic apoptosis pathway in hepatitis C virus patients: apoptosis fibrosis crosstalk.
    Eur J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1097/MEG.0000000000001603.
    PubMed     Abstract available


  62. SU C, Jin C, Han J, Hu X, et al
    Ultrasonographic assessment of right heart intracardiac mass in patients with hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2019 Nov 8. doi: 10.1097/MEG.0000000000001589.
    PubMed     Abstract available


  63. GOZDAS HT, Ince N
    Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001599.
    PubMed     Abstract available


  64. SLIEM HA, Salem AS, Hussien WM, El Sayed HRA, et al
    Arterial wall structural changes in noncirrhotic chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019;31:1432-1438.
    PubMed     Abstract available


  65. WIEGAND J, Buggisch P, Mauss S, Boeker KHW, et al
    Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Eur J Gastroenterol Hepatol. 2019;31:1424-1431.
    PubMed     Abstract available


    October 2019
  66. WANG Y, Li XY, Wu LL, Zheng XY, et al
    Dynamic prediction of liver cirrhosis risk in chronic hepatitis B patients using longitudinal clinical data.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001592.
    PubMed     Abstract available


  67. EL-KHAYAT H, Kamal EM, Mahmoud H, Gomaa A, et al
    Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001581.
    PubMed     Abstract available


  68. HEIL J, Soufidi K, Stals F, Frantzen H, et al
    Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001593.
    PubMed     Abstract available


  69. MANOLAKOPOULOS S, Striki A, Papastergiou V, Perlepe N, et al
    Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001558.
    PubMed     Abstract available


  70. TACHI Y, Hirai T, Kojima Y, Tachino H, et al
    Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001539.
    PubMed     Abstract available


  71. PAPE S, Nevens F, Verslype C, Mertens C, et al
    Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience.
    Eur J Gastroenterol Hepatol. 2019 Oct 24. doi: 10.1097/MEG.0000000000001580.
    PubMed     Abstract available


  72. FERREIRA G, Stuurman AL, Horsmans Y, Cattaert T, et al
    Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001537.
    PubMed     Abstract available


  73. CHEN PC, Chen BH, Huang CH, Jeng WJ, et al
    Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and sp
    Eur J Gastroenterol Hepatol. 2019;31:1256-1263.
    PubMed     Abstract available


    September 2019
  74. ABBAS OM, Khalifa KAE, Makhlouf MM, Osman NF, et al
    Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001547.
    PubMed     Abstract available


  75. MORALES-ARRAEZ D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, et al
    Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001534.
    PubMed     Abstract available


  76. MORALES-ARRAEZ D, Diaz-Flores F, Alonso A, de Vera A, et al
    Patients with suboptimal hepatitis B virus diagnostic characterization are at risk of liver fibrosis progression.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001527.
    PubMed     Abstract available


  77. KIM MN, Lee JH, Chon YE, Ha Y, et al
    Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001520.
    PubMed     Abstract available


  78. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001512.
    PubMed     Abstract available


  79. FAN Y, Zhou S, Li C, Ma B, et al
    The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction.
    Eur J Gastroenterol Hepatol. 2019;31:1167-1168.
    PubMed    


    August 2019
  80. DURCAN E, Hatemi I, Sonsuz A, Canbakan B, et al
    The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001501.
    PubMed     Abstract available


  81. CHEN J, Shi X, Luo T, Zhao Y, et al
    The correlations between hepatitis B virus infection and hepatocellular carcinoma with portal vein tumor thrombus or extrahepatic metastasis.
    Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001514.
    PubMed     Abstract available


  82. SARWAR S, Tarique S, Aleem A, Khan AA, et al
    Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
    Eur J Gastroenterol Hepatol. 2019;31:1035-1039.
    PubMed     Abstract available


    July 2019
  83. YU ZJ, Zhang LL, Huang TT, Zhu JS, et al
    Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2019;31:873-877.
    PubMed     Abstract available


  84. HWAN YJ, Shin J, Jin YJ, Lee JW, et al
    Comparison of clinical manifestations and outcomes of noncirrhotic and cirrhotic hepatocellular carcinoma patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Jul 1. doi: 10.1097/MEG.0000000000001478.
    PubMed     Abstract available


    June 2019
  85. GARIOUD A, Heng R, Amiot X, Remy AJ, et al
    Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
    Eur J Gastroenterol Hepatol. 2019 Jun 18. doi: 10.1097/MEG.0000000000001450.
    PubMed     Abstract available


  86. CHEN B, Pang L, Cao H, Wu D, et al
    Autologous stem cell transplantation for patients with viral hepatitis-induced liver cirrhosis: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2019 Jun 14. doi: 10.1097/MEG.0000000000001455.
    PubMed     Abstract available


    May 2019
  87. HANAFY AS, Seleem WM, Basha MAA, Marei AM, et al
    Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: a dogma or fiction.
    Eur J Gastroenterol Hepatol. 2019 May 29. doi: 10.1097/MEG.0000000000001459.
    PubMed     Abstract available


  88. YUAN X, Duan SZ, Cao J, Gao N, et al
    Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients.
    Eur J Gastroenterol Hepatol. 2019 May 17. doi: 10.1097/MEG.0000000000001437.
    PubMed     Abstract available


  89. WANG H, Wang J, Huang R, Xia J, et al
    Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2019 May 16. doi: 10.1097/MEG.0000000000001447.
    PubMed     Abstract available


  90. COSTA M, Rojas Rojas T, Lacoste D, Villes V, et al
    Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441.
    PubMed     Abstract available


  91. TADA T, Toyoda H, Yasuda S, Miyake N, et al
    Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
    Eur J Gastroenterol Hepatol. 2019 May 6. doi: 10.1097/MEG.0000000000001434.
    PubMed     Abstract available


  92. OUBINA JR, Delfino CM, Mathet VL
    Hepatitis D virus infection in patients with hepatitis B virus occult infection.
    Eur J Gastroenterol Hepatol. 2019;31:646.
    PubMed    


    April 2019
  93. CHALOUNI M, Sogni P, Miailhes P, Lacombe K, et al
    Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.
    Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001408.
    PubMed     Abstract available


  94. HAMIDI AA, Oncul A, Ozguven BY, Sevgi DY, et al
    Diagnostic accuracy of different noninvasive scores for detecting advanced fibrosis in chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001428.
    PubMed     Abstract available


  95. SORIANO V, Aguilera A, Gonzalez R, Gomez-Gallego F, et al
    Occult hepatitis B and HIV infection.
    Eur J Gastroenterol Hepatol. 2019 Apr 8. doi: 10.1097/MEG.0000000000001417.
    PubMed     Abstract available


  96. POST G, Shalev N, Baumgarten A, Shimakawa Y, et al
    Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001409.
    PubMed     Abstract available


  97. EMORI CT, Uehara SNO, Carvalho-Filho RJ, Amaral AC, et al
    Changing pattern of chronic hepatitis C in renal transplant patients over 20 years.
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001404.
    PubMed     Abstract available



  98. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy: Erratum.
    Eur J Gastroenterol Hepatol. 2019;31:549.
    PubMed    


  99. ABD-ELSALAM S, Arafa M, Elkadeem M, Elfert A, et al
    Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.
    Eur J Gastroenterol Hepatol. 2019;31:499-502.
    PubMed     Abstract available


    March 2019
  100. ILIAZ R, Yuce T, Torun S, Cavus B, et al
    Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis.
    Eur J Gastroenterol Hepatol. 2019 Mar 25. doi: 10.1097/MEG.0000000000001406.
    PubMed     Abstract available


  101. FOUAD R, Elsharkawy A, Abdel Alem S, El Kassas M, et al
    Clinical impact of serum alpha-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2019 Mar 20. doi: 10.1097/MEG.0000000000001400.
    PubMed     Abstract available


  102. EL-MAKSOUD MA, Habeeb MR, Ghazy HF, Nomir MM, et al
    Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2019 Mar 11. doi: 10.1097/MEG.0000000000001388.
    PubMed     Abstract available


  103. DARWEESH SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, et al
    Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001385.
    PubMed     Abstract available


  104. MUSHTAQ S, Ghani E, Azam K, Hussain T, et al
    Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography.
    Eur J Gastroenterol Hepatol. 2019;31:357-362.
    PubMed     Abstract available


    February 2019
  105. LIAN MJ, Zhang JQ, Chen SD, Zhang DD, et al
    Diagnostic accuracy of gamma-glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001381.
    PubMed     Abstract available


  106. SANDMANN L, Dorge P, Wranke A, Vermehren J, et al
    Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386.
    PubMed     Abstract available


  107. KOUKOULIOTI E, Brodzinski A, Mihm U, Sarrazin C, et al
    Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections.
    Eur J Gastroenterol Hepatol. 2019 Feb 15. doi: 10.1097/MEG.0000000000001351.
    PubMed     Abstract available


  108. DARWEESH SK, Gad AA, Akroof K, ElLatif ZA, et al
    Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Eur J Gastroenterol Hepatol. 2019 Feb 4. doi: 10.1097/MEG.0000000000001377.
    PubMed     Abstract available


  109. SUAREZ E, Buti M, Rodriguez M, Prieto M, et al
    Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
    Eur J Gastroenterol Hepatol. 2019;31:267-271.
    PubMed     Abstract available


  110. HU Z, Ni P, Fan X, Men R, et al
    Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
    Eur J Gastroenterol Hepatol. 2019;31:277.
    PubMed    


  111. MARCELLIN F, Protopopescu C, Wittkop L, Salmon-Ceron D, et al
    No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Eur J Gastroenterol Hepatol. 2019;31:274-276.
    PubMed    


  112. FAROOQUI MT, Khan MA, Cholankeril G, Khan Z, et al
    Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2019;31:149-156.
    PubMed     Abstract available


    January 2019
  113. ISMAIL WA, Yousef AE
    Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.
    Eur J Gastroenterol Hepatol. 2019 Jan 29. doi: 10.1097/MEG.0000000000001370.
    PubMed     Abstract available


  114. YU JH, Suh YJ, Jin YJ, Heo NY, et al
    Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
    Eur J Gastroenterol Hepatol. 2019 Jan 28. doi: 10.1097/MEG.0000000000001357.
    PubMed     Abstract available


  115. EL-KHAYAT H, Kamal EM, Yakoot M, Gawad MA, et al
    Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients.
    Eur J Gastroenterol Hepatol. 2019 Jan 22. doi: 10.1097/MEG.0000000000001360.
    PubMed     Abstract available


  116. ORMECI N, Sezgin O, Karaali R, Aygen B, et al
    Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
    Eur J Gastroenterol Hepatol. 2019 Jan 21. doi: 10.1097/MEG.0000000000001334.
    PubMed     Abstract available


  117. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.
    Eur J Gastroenterol Hepatol. 2019;31:24-28.
    PubMed     Abstract available


    December 2018
  118. WU ZX, Chen FS, Zhou XL, Huang Q, et al
    Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study.
    Eur J Gastroenterol Hepatol. 2018 Dec 31. doi: 10.1097/MEG.0000000000001345.
    PubMed     Abstract available


  119. HU J, Zhang X, Gu J, Yang M, et al
    Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Dec 12. doi: 10.1097/MEG.0000000000001336.
    PubMed     Abstract available


  120. PONZETTO A, Ciancio A, Figura N
    Delta hepatitis in resolved hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:1528.
    PubMed    


  121. SHEHATA HH, Elfert AA, Abdin AA, Soliman SM, et al
    Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy.
    Eur J Gastroenterol Hepatol. 2018;30:1476-1481.
    PubMed     Abstract available


    November 2018
  122. LYBECK C, Brenndorfer ED, Sallberg M, Montgomery SM, et al
    Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.
    Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316.
    PubMed     Abstract available


  123. DEMERDASH HM, Elyamany AS, Arida E
    Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001306.
    PubMed     Abstract available


  124. SHAH SM, Baniya JB, Gupta BP, Shrestha A, et al
    Association between liver fibrosis and hepatitis E seroprevalence among HIV-positive individuals in Nepal.
    Eur J Gastroenterol Hepatol. 2018 Nov 5. doi: 10.1097/MEG.0000000000001308.
    PubMed     Abstract available


  125. OZARAS R, Uraz S, Demirel A, Mete B, et al
    Resolved hepatitis B virus infection: an unresolved issue of terminology.
    Eur J Gastroenterol Hepatol. 2018;30:1389.
    PubMed    


    October 2018
  126. SHAHID M, Idrees M, Butt AM, Raza SM, et al
    Hepatitis C and G virus coinfection in Punjab, Pakistan: incidence and its correlation analysis with clinical data.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001302.
    PubMed     Abstract available


  127. LV DD, Wang ML, Chen EQ, Wu DB, et al
    A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001299.
    PubMed     Abstract available


  128. DRIEDGER M, Galanakis C, Doyle MA, Cooper CL, et al
    Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu.
    Eur J Gastroenterol Hepatol. 2018 Oct 30. doi: 10.1097/MEG.0000000000001292.
    PubMed     Abstract available


  129. SHAH T, Hussain W, Ali N, Sardar S, et al
    Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study.
    Eur J Gastroenterol Hepatol. 2018 Oct 24. doi: 10.1097/MEG.0000000000001287.
    PubMed     Abstract available


  130. KRUGER K, Krauth C, Rossol S, Mauss S, et al
    Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-registry.
    Eur J Gastroenterol Hepatol. 2018 Oct 15. doi: 10.1097/MEG.0000000000001283.
    PubMed     Abstract available


  131. IBRAHIM EH, Marzouk SA, Zeid AE, Lashen SA, et al
    Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 2. doi: 10.1097/MEG.0000000000001272.
    PubMed     Abstract available


  132. LI B, Zhang L, Zhang Z, Yan G, et al
    A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 1. doi: 10.1097/MEG.0000000000001281.
    PubMed     Abstract available


  133. VAN SANTEN DK, Schim van der Loeff MF, Cartier van Dissel J, Martens JPD, et al
    High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.
    Eur J Gastroenterol Hepatol. 2018;30:1168-1176.
    PubMed     Abstract available


    September 2018
  134. ESSA M, Sabry A, Abdelsameea E, Tharwa ES, et al
    Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Sep 21. doi: 10.1097/MEG.0000000000001250.
    PubMed     Abstract available


  135. ATTIA D, Deterding K, Cornberg J, Gebel MJ, et al
    Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Eur J Gastroenterol Hepatol. 2018 Sep 19. doi: 10.1097/MEG.0000000000001259.
    PubMed     Abstract available


  136. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001264.
    PubMed     Abstract available


  137. STOURNARAS E, Neokosmidis G, Stogiannou D, Protopapas A, et al
    Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254.
    PubMed     Abstract available


  138. FUKUI A, Kawabe N, Hashimoto S, Kamei H, et al
    Skeletal muscle mass depletion in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001255.
    PubMed     Abstract available


    August 2018
  139. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Abstract available


  140. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Abstract available


  141. EL-NAHAAS SM, Fouad R, Elsharkawy A, Khairy M, et al
    High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228.
    PubMed     Abstract available


  142. GAYAM V, Tiongson B, Khalid M, Mandal AK, et al
    Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001233.
    PubMed     Abstract available


  143. ALI N, Hussain W, Hayat A, Shah T, et al
    Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study.
    Eur J Gastroenterol Hepatol. 2018 Aug 3. doi: 10.1097/MEG.0000000000001220.
    PubMed     Abstract available


    July 2018
  144. SONG BG, Sinn DH, Chi S, Kim K, et al
    Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
    Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001226.
    PubMed     Abstract available


  145. ELHELBAWY M, Abdel-Razek W, Alsebaey A, Hashim M, et al
    Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001215.
    PubMed     Abstract available


  146. ABDELAZIZ AO, Shousha HI, Said EM, A Soliman Z, et al
    Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2018 Jul 17. doi: 10.1097/MEG.0000000000001196.
    PubMed     Abstract available


  147. SOLUND C, Andersen ES, Mossner B, Laursen AL, et al
    Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192.
    PubMed     Abstract available


  148. HILL LA, Delmonte RJ, Andrews B, Richards L, et al
    Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Jul 2. doi: 10.1097/MEG.0000000000001195.
    PubMed     Abstract available


  149. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed    


  150. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed    


  151. COMBA A, Demirbas F, Caltepe G, Eren E, et al
    Retrospective analysis of children with alpha-1 antitrypsin deficiency.
    Eur J Gastroenterol Hepatol. 2018;30:774-778.
    PubMed     Abstract available


    June 2018
  152. VIEJO LG, Herola AG, Lloret IS, Ruano FS, et al
    Screening of hepatitis C virus infection in adult general population in Spain.
    Eur J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1097/MEG.0000000000001190.
    PubMed     Abstract available


  153. AGUILERA A, Rodriguez-Calvino J, de Mendoza C, Soriano V, et al
    Hepatitis delta in patients with resolved hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2018 Jun 20. doi: 10.1097/MEG.0000000000001187.
    PubMed     Abstract available


  154. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Abstract available


    May 2018
  155. YOON CH, Jin YJ, Lee JW
    Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Eur J Gastroenterol Hepatol. 2018 May 29. doi: 10.1097/MEG.0000000000001174.
    PubMed     Abstract available


  156. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Abstract available


  157. AGUILERA A, Trastoy R, Rodriguez-Calvino J, Manso T, et al
    Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.
    Eur J Gastroenterol Hepatol. 2018 May 8. doi: 10.1097/MEG.0000000000001163.
    PubMed     Abstract available


  158. CHEN B, Wang YH, Qian JQ, Wu DB, et al
    Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis.
    Eur J Gastroenterol Hepatol. 2018 May 3. doi: 10.1097/MEG.0000000000001156.
    PubMed     Abstract available


  159. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Abstract available


  160. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed    


  161. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Abstract available


  162. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Abstract available


    April 2018
  163. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Abstract available


  164. SPAHR L, Goossens N, Furrer F, Dupuis M, et al
    A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001148.
    PubMed     Abstract available


  165. GOKCE O, Ozenirler S, Atak Yucel A, Oruklu N, et al
    Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Apr 20. doi: 10.1097/MEG.0000000000001123.
    PubMed     Abstract available


  166. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Abstract available


  167. SPINICCI M, Emmi G, Dies L, Barilaro A, et al
    Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Eur J Gastroenterol Hepatol. 2018 Apr 11. doi: 10.1097/MEG.0000000000001132.
    PubMed     Abstract available


  168. SU YC, Lin PC, Yu HC, Wu CC, et al
    Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2018 Apr 4. doi: 10.1097/MEG.0000000000001130.
    PubMed     Abstract available


  169. EFE C, Ozaslan E, Purnak T
    Second-line immunosuppressants for autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2018;30:490-491.
    PubMed    


  170. PONZETTO A, Figura N
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018;30:490.
    PubMed    


  171. POYNARD T, Munteanu M, Charlotte F, Perazzo H, et al
    Impact of steatosis and inflammation definitions on the performance of NASH tests.
    Eur J Gastroenterol Hepatol. 2018;30:384-391.
    PubMed     Abstract available


    March 2018
  172. TONON M, Piano S, Romano A, Fasolato S, et al
    Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
    Eur J Gastroenterol Hepatol. 2018;30:284-290.
    PubMed     Abstract available


    February 2018
  173. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Abstract available


  174. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Abstract available


  175. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Abstract available


  176. ZHANG Y, Shi Y, Wu R, Wang X, et al
    Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.
    Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001100.
    PubMed     Abstract available


  177. HUANG R, Zhao XA, Wang J, Hao Y, et al
    Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:241.
    PubMed    


  178. ZHANG X, Qi X, Yoshida EM, Mendez-Sanchez N, et al
    Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes.
    Eur J Gastroenterol Hepatol. 2018;30:233-240.
    PubMed     Abstract available


    January 2018
  179. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Abstract available


  180. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Abstract available


  181. PANG Q, Zhou L, Qu K, Cui RX, et al
    Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Eur J Gastroenterol Hepatol. 2018;30:60-70.
    PubMed     Abstract available


    December 2017
  182. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Abstract available


  183. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Abstract available


  184. DE LEMOS-BONOTTO M, Valle-Tovo C, Costabeber AM, Mattos AA, et al
    A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    Eur J Gastroenterol Hepatol. 2017 Dec 8. doi: 10.1097/MEG.0000000000001019.
    PubMed     Abstract available


  185. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Abstract available


    November 2017
  186. LIN Z, Liang J, Zhu J, Hu C, et al
    Diverse correlations between fibrosis-related factors and liver stiffness measurement by transient elastography in chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001023.
    PubMed     Abstract available


  187. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Abstract available


  188. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Abstract available


  189. HUANG R, Wang J, Zhao XA, Xia J, et al
    The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017;29:1314.
    PubMed    


    October 2017
  190. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Abstract available


  191. SIMONETTI G, Gitto S, Golfieri L, Gamal N, et al
    Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000000999.
    PubMed     Abstract available


  192. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Abstract available


  193. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Abstract available


  194. ABDEL-RAZIK A, Mousa N, Zakaria S, Elhelaly R, et al
    New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume.
    Eur J Gastroenterol Hepatol. 2017 Oct 13. doi: 10.1097/MEG.0000000000000982.
    PubMed     Abstract available


  195. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed    


    September 2017
  196. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Abstract available


  197. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Abstract available


  198. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Abstract available


  199. LANG S, Kutting F, Staub A, Schramowski J, et al
    Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Sep 6. doi: 10.1097/MEG.0000000000000977.
    PubMed     Abstract available


  200. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Abstract available


  201. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Abstract available


  202. TRIANTOS C, Kalafateli M, Aggeletopoulou I, Mandellou M, et al
    Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    Eur J Gastroenterol Hepatol. 2017;29:998-1003.
    PubMed     Abstract available


    August 2017
  203. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Abstract available


  204. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Abstract available


  205. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Abstract available


  206. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Abstract available


  207. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Abstract available


    July 2017
  208. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Abstract available


    June 2017
  209. FERNANDES SR, Marques da Costa P, Vitor S, Carvalho JR, et al
    Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2017 Jun 16. doi: 10.1097/MEG.0000000000000926.
    PubMed     Abstract available


  210. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Abstract available


    May 2017
  211. SERIGADO JM, Izzy M, Kalia H
    Novel therapies and potential therapeutic targets in the management of chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000911.
    PubMed     Abstract available


  212. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Abstract available


  213. WANG PC, Wei TY, Tseng TC, Lin HH, et al
    Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000897.
    PubMed     Abstract available


  214. JABLONKA A, Solbach P, Wobse M, Manns MP, et al
    Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015.
    Eur J Gastroenterol Hepatol. 2017 May 10. doi: 10.1097/MEG.0000000000000889.
    PubMed     Abstract available


  215. HUANG R, Xia J, Liu Y, Zhang Z, et al
    Acoustic radiation force impulse in the diagnosis of liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000902.
    PubMed    


  216. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed    


  217. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Abstract available


  218. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Abstract available


  219. IINO C, Shimoyama T, Igarashi T, Aihara T, et al
    Usefulness of the Glasgow-Blatchford score to predict 1-week mortality in patients with esophageal variceal bleeding.
    Eur J Gastroenterol Hepatol. 2017;29:547-551.
    PubMed     Abstract available


  220. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Abstract available


    April 2017
  221. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Abstract available


  222. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Abstract available


  223. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Abstract available


    March 2017
  224. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Abstract available


  225. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed    


  226. MURATORI P, Efe C, Muratori L, Ozaslan E, et al
    Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000870.
    PubMed     Abstract available


  227. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Abstract available


    February 2017
  228. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Abstract available


    January 2017
  229. ZHU S, Waili Y, Qi X, Chen Y, et al
    Lymphocyte-monocyte ratio at admission predicts possible outcomes in patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2017;29:31-35.
    PubMed     Abstract available


  230. PAPADOPOULOS N, Deutsch M, Manolakopoulos S, Bitsi C, et al
    Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017;29:56-60.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: